Bristol Myers Stock

BMY Stock: A Break Above $57.50 Will Set the Wheels in Motion The pharmaceutical names are back in the limelight, and this time it's for all the right reasons. It is why I am focusing on Bristol-Myers Squibb Co (NYSE:BMY) stock. There are a number of indications on the BMY stock…

BMY Stock: All of Sudden, Upside Is Expected All of sudden, a rally has engulfed the pharmaceutical sector. Bids are racking up and they are driving up individual names. This push has done a number on Bristol-Myers Squibb Co (NYSE:BMY) and the Bristol Myers stock chart, where a number…

BMY Stock: More Pain Bristol-Myers Squibb Co (NYSE:BMY) stock was pounded with selling pressure after a news release hit the news wires with the announcement that the company will no longer seek accelerated approval of its immunotherapy cancer drug “Opdivo." By the time the closing bell rang on Friday,…

BMY Stock: Further Downside On Wednesday, January 11, 2017, President-elect Donald Trump attacked drug makers in a press conference and accused them of "getting away with murder." This "murder" reference was in regards to their predatory pricing polices that have been scrutinized by the mainstream media. This comment caused…

BMY Stock Is Trending Lower Bristol-Myers Squibb Co (NYSE:BMY) stock is still feeling the after-effects of the negative news surrounding its cancer drug “Opdivo,” which failed a study that would have expanded its use in lung cancer patients. This bad news is further compounded, as the entire pharmaceutical…

BMY Stock: Teetering on the Edge Bristol-Myers Squibb Co (NYSE:BMY) stock dropped 16% after news broke that their cancer drug “Opdivo” failed a study that would have expanded its use in lung cancer patients. The stock price gapped lower as the news disseminated outside of regular trading hours.…